NEW YORK (GenomeWeb News) — Becton Dickinson today said that fiscal second-quarter revenues rose 11 percent as R&D spending decreased 32 percent and profit swelled 57 percent.
Total receipts for the three months ended March 31 increased to $1.6 billion from $1.4 billion year over year.
BD said revenues from its Diagnostics segment increased 11 percent to $473 million, while Biosciences revenue rose 13 percent to $258.5 million. Revenue from the Medical segment rose 10 percent to $844.1 million.
The company also said that Tripath Imaging, which BD acquired late last year, contributed $27 million in second quarter sales.
R&D spending for the quarter decreased to $86.7 million from $127.7 million year over year.
Net profits for the quarter increased to $242.5 million from $154.1 million in the year-ago period.
The company did not disclose its balance sheet for the period.